Skip to content

Avanos Medical AVNS Operating Income

Operating Income at other companies

Evommune
 logo
Evommune EVMN
-$682.81K-2,027%
CHE
ChemedCHE
$84.58M-10.7%
RBC Bearings logo
RBC BearingsRBC
$119.1M+18.3%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$117.42M+20.0%
SBA Communications logo
SBA CommunicationsSBAC
$342.85M+2.4%
CSX logo
CSXCSX
$1.25B+20.4%

Other financials

Income statement

See full
Revenue$182.2M+8.8%
Gross profit$94.2M+4.9%
Operating income$8.9M-13.6%
Net income$5.1M-22.7%
EPS (diluted)$0.11-21.4%

Balance sheet

See full
Cash & equivalents$65.6M-32.4%
Total debt$138.4M-1.8%
Total equity$782.1M-6.8%
Total assets$1.1B-5.2%

Cash flow

See full
Operating cash flow-$12.3M-148%
CapEx$4.3M-35.8%
Free cash flow-$16.6M-187%

Valuation

See full
Market cap$1.17B+108%
Enterprise value$1.24B+105%
P/S1.6×+0.8×

Profitability

See full
Gross margin50%-4.6pp
Operating margin-9.1%-4.2pp
Net margin-10.4%-4.7pp
FCF margin1.6%-14.9pp

Returns & leverage

See full
Return on equity-9.2%-3.9pp
Debt / equity0.2×0.0×
Current ratio2.5×-0.1×

Where this comes from

Reported directly by Avanos Medical in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Avanos Medical’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avanos Medical's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Avanos Medical's operating income?
Avanos Medical (AVNS) reported operating income of $8.9M in Q1 2026.
How has Avanos Medical's operating income changed year-over-year?
Avanos Medical's operating income decreased by 13.6% year-over-year, from $10.3M to $8.9M.
What is the long-term trend for Avanos Medical's operating income?
Over 4 years (2021 to 2025), Avanos Medical's operating income has grown at a 13.4% compound annual growth rate (CAGR), from -$38.7M to -$64.1M.
What does operating income mean?
Measures the profit or loss generated from core business operations after deducting cost of goods sold and operating expenses. It is a key indicator of the company's ability to generate sustainable earnings from its primary medical device activities.